
Krishnan Ramaswamy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7607387/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 556-569.	10.7	90
2	Overall survival by race in chemotherapy-naÃ ⁻ ve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide Journal of Clinical Oncology, 2019, 37, 212-212.	1.6	30
3	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases, 2021, 24, 1032-1040.	3.9	28
4	Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 524-530.	3.9	14
5	Economic Outcomes in Patients with Chemotherapy-NaÃ ⁻ ve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in Therapy, 2020, 37, 2083-2097.	2.9	12
6	Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 889-897.	0.9	4
7	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	2
8	PD15-11â€∫SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAà VE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE. Journal of Urology, 2019, 201, .	0.4	1